PF-06741086 Multiple Dose Study in Severe Hemophilia
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 12/20/2018 |
| Start Date: | March 8, 2017 |
| End Date: | December 3, 2018 |
A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Or Intravenous Pf-06741086 In Subjects With Severe Hemophilia
This study is designed to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of
PF-06741086 in subjects with severe hemophilia.
pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of
PF-06741086 in subjects with severe hemophilia.
Inclusion Criteria:
- Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%), including patients
with inhibitors to Factor VIII or Factor IX
- Episodic (on-demand) treatment regimen prior to screening
- At least 6 acute bleeding episodes during the 6-month period prior to screening
Exclusion Criteria:
- Known coronary artery, thrombotic, or ischemic disease
- Currently receiving treatment for acute bleeding episodes with APCC and cannot
substitute treatment with rFVIIa
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
Click here to add this to my saved trials